Navigation Links
Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
Date:5/5/2013

Claremont CA (PRWEB) May 05, 2013

Removing embedded bacteria from biofilms in wounds remains a challenge to doctors and caregivers. Likewise, veterinarians face similar challenges treating their zoo patients. Synedgen will report compelling data on new treatments against wound biofilms at a poster session at the 113th General Meeting of the American Society for Microbiology (asm2013) on May 18-21, 2013, at the Colorado Convention Center in Denver Colorado.

The poster, Antibacterial and Wound Healing Enhancement of PAAG in Minor Species, highlights the antibacterial and biofilm-reducing activity of Synedgen’s Synoplex® rinse. Data will be presented for efficacy against bacteria from elephant wounds and for Klebsiella pneumoniae biofilms. Data from additional collaborative studies evaluating Synoplex in the treatment of chronic elephant and rhinoceros wounds, including foot-disease, pressure ulcers, and infected glands that were not responding well to conventional treatment will also be presented. Synoplex is approved for marketing by the FDA as a treatment for wounds in elephants and rhinoceros.

Bacteria isolated from elephant wounds were all reduced more than 1000 fold after 1-hour treatment with Synoplex. K. pneumonia biofilms were reduced by more than 1000 fold after 5-hour treatment. Epithelial cells, which are responsible for the initial stages of regeneration of tissue, grew to cover at least twice more surface area than other wound treatments and control. Treated minor species showed significant improvement in wound healing and successful resolution of most wounds.
Synedgen’s VP of Research Stacy Townsend PhD will present the results on Tuesday May 21, 2013 at 1:00 PM - 2:45 PM at Poster board # 2194.

“As demonstrated by these studies, Synoplex provides a highly effective prophylactic and therapeutic treatment for controlling and preventing bacterial biofilms associated with chronic and acute dermal wounds including foot disease in minor species,” remarked Townsend. “The non-toxic nature of Synoplex is also beneficial in a large animal setting.”

Synoplex is available directly from Synedgen. For pricing and ordering information, please contact Synedgen at info(at)synedgen(dot)com.

About Synedgen

Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10700553.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen Announces Issuance of Patent to Optimize Animal Health
2. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
3. Small Business Online SEO Class Enrolling Now, Announces JM Internet
4. Anthera Announces First Quarter 2013 Financial Report and Conference Call
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... (PRWEB) , ... May 22, 2017 , ... ... year in a row in the Aragon Research Globe™ for Corporate Learning, 2017. ... with industry direction and market demand, and effectively perform against those strategies. NetDimensions’ ...
(Date:5/23/2017)... Philadelphia, PA. (PRWEB) , ... May 23, 2017 ... ... Clinical Works as Vice President of Clinical Operations. She brings years ... Pharmaceuticals, and Yaupon Therapeutics. From her professional foundation as a licensed occupational therapist, ...
(Date:5/22/2017)... MA (PRWEB) , ... May 22, 2017 , ... Stratevi, ... has expanded to the East Coast. It has opened an office in downtown Boston ... therapies are finding it increasingly more important to generate evidence on the value they ...
(Date:5/21/2017)... ... 20, 2017 , ... CNSDose is a genetically driven, clinically ... by finding the right antidepressant faster. CNSDose speeds recovery and reduces side ... personalized approach to treatment. , A peer-reviewed and published, 12-week double-blind ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):